Findings from a nationwide, multicenter study led by Johns Hopkins Medicine and the Johns Hopkins Bloomberg School of Public Health suggest that patients with COVID-19 have less chance of developing post-COVID conditions -; commonly known as long COVID -; if they receive early treatment with plasma from convalescent (recovered) COVID patients that contain antibodies against SARS-CoV-2, the virus that causes COVID-19.
FDA offers positive signals for potential pediatric neuroblastoma drug ahead of ODAC meeting
The FDA’s Oncologic Drugs Advisory Committee tomorrow will review US WorldMeds’ potential high-risk pediatric neuroblastoma drug to reduce the risk of relapse after front-line therapy.
October 4, 2023